Protara Therapeutics, Inc. financial data

Symbol
TARA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, 3 Rd Floor, New York, New York
Fiscal year end
December 31
Former names
ArTara Therapeutics, Inc. (to 4/23/2020), PROTEON THERAPEUTICS INC (to 12/31/2019)
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24K % -37.1%
Debt-to-equity 14.5 % +67.1%
Return On Equity -58.8 % -10.2%
Return On Assets -51.4 % -4.58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.4M shares +1.12%
Common Stock, Shares, Outstanding 11.4M shares +1.12%
Entity Public Float 18M USD -8.16%
Common Stock, Value, Issued 11K USD 0%
Weighted Average Number of Shares Outstanding, Basic 11.4M shares +1.04%
Weighted Average Number of Shares Outstanding, Diluted 11.4M shares +1.04%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 27.6M USD +65.4%
General and Administrative Expense 18.1M USD -8.03%
Operating Income (Loss) -45.7M USD +30.6%
Nonoperating Income (Expense) 3.26M USD +94.4%
Net Income (Loss) Attributable to Parent -42.5M USD +33.9%
Earnings Per Share, Basic -3.74 USD/shares +34.4%
Earnings Per Share, Diluted -3.74 USD/shares +34.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.2M USD +148%
Marketable Securities, Current 2.99M USD -95.4%
Other Assets, Current 3K USD -97.6%
Assets, Current 57.9M USD -38.8%
Property, Plant and Equipment, Net 1.21M USD -20.3%
Operating Lease, Right-of-Use Asset 5.02M USD -17%
Goodwill 29.5M USD 0%
Other Assets, Noncurrent 31K USD -94.7%
Assets 68.1M USD -36%
Accounts Payable, Current 972K USD -76.2%
Accrued Liabilities, Current 3.53M USD +153%
Liabilities, Current 5.5M USD -14.2%
Operating Lease, Liability, Noncurrent 4.23M USD -19.1%
Liabilities 9.73M USD -16.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +99.8%
Retained Earnings (Accumulated Deficit) -211M USD -25.1%
Stockholders' Equity Attributable to Parent 58.4M USD -38.4%
Liabilities and Equity 68.1M USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD +19.5%
Net Cash Provided by (Used in) Financing Activities -76K USD -18.8%
Net Cash Provided by (Used in) Investing Activities 23.1M USD +134%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 11.4M shares +1.12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 53M USD +143%
Deferred Tax Assets, Valuation Allowance 52.7M USD +35.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 54.3M USD +34.2%
Operating Lease, Liability 5.23M USD
Depreciation 83K USD +7.79%
Payments to Acquire Property, Plant, and Equipment 45K USD -62.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -42M USD +34.1%
Lessee, Operating Lease, Liability, to be Paid 6.05M USD
Property, Plant and Equipment, Gross 2.12M USD +2.17%
Operating Lease, Liability, Current 1M USD +7.18%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.43M USD +7.69%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +40.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) -13.8M USD -52.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 826K USD -32.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD +2.44%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +14.8%
Deferred Federal Income Tax Expense (Benefit) -9.63M USD -21%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 718K USD -49.8%
Operating Lease, Payments 332K USD 0%
Additional Paid in Capital 270M USD +2.13%
Share-based Payment Arrangement, Expense 5.74M USD -10%
Deferred State and Local Income Tax Expense (Benefit) -4.12M USD -286%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%